Genetic testing firm 23andMe is going public via a SPAC backed by Richard Branson
“We have always believed that healthcare needs to be driven by the consumer, and we have a huge opportunity to help personalize the entire experience at scale, allowing individuals to be more proactive about their health and wellness,” 23andMe CEO and co-founder Anne Wojcicki said in a statement.
The deal values the company at $3.5 billion, and current shareholders will own 81 percent of the company. Wojcicki and Branson each invested $25 million themselves as part of the $250 million fund formed to take the company public. The deal is expected to close in the…